南京安维士传动技术股份有限公司
100-499人
公司优势
安维士为国内外风机传动链（主轴、主齿轮箱）及偏航、变桨提供全生命周期服务。公司可向风场业主提供培训服务、检测服务、油品业务、空中维修、返厂维修、流体产品、备机方案、交换方案、替代方案、备品备件、偏航变桨、置换回收服务。作为南高齿***指定的齿轮箱专业服务提供商，安维士可为NGC产品及其他非NGC产品提供专业服务。
安维士秉持“技术与服务并重，对客户负责”的一贯作风，在中国风电市场内已为超过20家知名发电集团、1800多个风场、70000多台次的齿轮箱提供过运维服务和技术支持。
安维士期待您的加入！！
热招职位
相关职位
热门城市
20,861+ 岗位更新等你来订阅
一键订阅最新的岗位，每周送达
🎉恭喜你，订阅成功
继续订阅您可以在邮箱中随时取消订阅
浙江华源颜料股份有限公司作为浙江升华的全资一级子公司，成立于1996年，其麾下拥有德清华博颜料有限公司、德清户田三峰颜料有限公司、广西永福华源科技有限公司以及焦作百利联合颜料有限公司等控股子公司。该公司占地面积达30万平方米，员工总数超过900人，2021年的总产值接近10亿元人民币。其产品销售网络广泛覆盖中国各省份、直辖市、自治区，并远销全球五大洲的80多个国家和地区。
公司专注于开展电子现货交易，亦即大宗农产品的中远期电子交易。这一举措是由国家推行，旨在支持农业发展，优化农产品流通。其交易模式以电子现货仓单为基本单位，依托计算机网络进行跨地区货物交易，并实现统一结算。公司坚决执行国家政策要求，确保所有经营活动遵循相关法律法规。
Guangzhou Runsheng Cytomed Technology Co., Ltd. is a Sino-foreign joint venture biotechnology enterprise dedicated to cell medicine R&D and clinical translational research. The founder and academic leader of the company, Professor Ruan Runsheng, holds a postdoctoral degree from the University of Zurich in Switzerland, is a senior researcher at the National University of Singapore's Department of Medicine, a chief researcher at the Institute of Bioengineering and Nanotechnology of the Singapore Science and Technology Agency, and a member of the European Society of Medical Oncology (ESMO). He has also been included in the US New Century 500 Scientists and the Marquis' Who's Who Yearbook of the United States. Professor Ruan Runsheng has long been committed to the research and development of cellular immunology, with his latest achievement being the Tvac？ tumor personalized precision combined immunotherapy technology.
Founded on September 24, 2019, in Nansha, Guangzhou, the company focuses on exploring and developing the clinical applications of Tvac？ tumor personalized precision combined immunotherapy technology. This technology uses genomics, proteomics, and other omics technologies along with tumor immunology to achieve individualized precision treatment, marking an important direction for future cancer treatments.
Currently, the company has established four platforms: bioinformatics, proteomics, peptide synthesis, and cellular immunity. These platforms are equipped with high-speed local servers and cloud platforms, ultra-high-throughput 106-channel peptide synthesizers, liquid mass spectrometers, PCR instruments, Elispot, flow cytometers, RTCA, and cell culture rooms. These advanced facilities ensure robust support for the screening of new antigens and the development of peptide drugs. The company has built a highly specialized technical R&D team leveraging its platform advantages. Core team members come from prestigious institutions such as the Hong Kong University of Science and Technology, Technical University of Denmark, Stanford University School of Medicine, Harvard Medical School, and Macquarie University in Australia, all holding master's or doctoral degrees. Their expertise spans molecular biology, biochemistry, tumor immunology, clinical medicine, and industrialization.
The company has established strategic partnerships with institutions such as the National University Hospital of Singapore, Guangdong-Hong Kong-Macao Greater Bay Area Postdoctoral Science and Technology Innovation Public Research Center, the First Affiliated Hospital of Sun Yat-sen University, the Second Affiliated Hospital of Guangzhou Medical College, Guangdong Provincial People's Hospital, and Guangzhou First People's Hospital. Tvac？ technology is undergoing steady clinical trials, with smooth progress. Plans are underway to submit an NDA for Tvac？ within the next three years, aiming for formal clinical application in tumor treatment. Simultaneously, the company is advancing other tumor cell therapy R&D and clinical translation projects.
In 2021, the company partnered with the Guangdong-Hong Kong-Macao Greater Bay Area Postdoctoral Science and Technology Innovation Public Research Center to establish a postdoctoral research station, continuously attracting and nurturing high-end biomedical talent. It aims to provide a platform for international researchers pursuing the dream of medical practice.
The company is currently staffed primarily by R&D personnel, with two foreign experts, and maintains a flexible organizational structure and fresh corporate culture. It is a dynamic and energetic cell medicine R&D team with international vision and top-tier standards. Moving forward, the company will closely align with market demands, applying professional technology to medical institutions and patients, and creating an innovative technology platform that integrates scientific development, talent cultivation, and shared benefits.
北京世通仁和数码科技有限公司，规模为50-150人，类型为民营公司，行业为餐饮业。